Firebrick Pharma has commenced commercial manufacturing and export of its new Nasodine Throat Spray, marking a significant step in its international expansion. The company also reported a 15% increase in cash sales and reduced operating costs, signalling improving financial health.
- Nasodine Throat Spray enters commercial manufacturing and Singapore market
- TGA export approval secured, with first orders received in Fiji
- User survey shows 96% effectiveness rating and 97% ease of use for Nasodine Nasal Spray
- 15% year-on-year growth in cash sales, driven by US market expansion
- Operating costs reduced by 34% compared to prior year quarter
New Product Launch and Market Expansion
Firebrick Pharma Limited (ASX, FRE) has taken a decisive step forward with the commercial manufacturing and export of its Nasodine Throat Spray, the first new product in its Nasodine range since the nasal spray launch in 2024. The company secured Therapeutic Goods Administration (TGA) export approval, enabling shipments to Singapore, where the product was released for export in mid-December 2025 and began shipping in early January 2026.
In Singapore, Firebrick’s licensing partner, Innorini Life Sciences, has initiated promotion of the throat spray to government hospitals, with broader retail pharmacy promotion planned for mid-2026. The product’s convenience and advantages over traditional povidone-iodine gargles position it well for adoption in this key market.
International Growth Strategy Gains Traction
The company outlined a clear international growth strategy at its November 2025 Annual General Meeting, highlighting expanded promotional efforts in the United States, increased pharmacy distribution in Singapore, and the launch of Nasodine Throat Spray in Fiji, where first orders were received in January 2026. Additionally, Firebrick is pursuing regulatory approval in the Philippines, with its registration dossier accepted for review by the Philippines FDA in January 2026.
Firebrick is also exploring opportunities in Southeast Asia and the Middle East, signalling ambition to broaden its global footprint beyond current markets.
Strong User Validation Supports Commercial Potential
A recent survey of approximately 300 verified users of Nasodine Nasal Spray revealed overwhelmingly positive feedback. Around 96% rated the product as effective or better, and 97% found it easy to use. Users cited its germ-killing properties and protection against respiratory infections as key reasons for adoption. Such strong user advocacy bodes well for sustained market penetration and scalability.
Improved Financial Discipline and Revenue Growth
Financially, Firebrick reported a 15% increase in cash sales for the December 2025 quarter compared to the same period in 2024, primarily driven by growth in the US market. While Singapore sales dipped due to prior pipeline filling ahead of the 2025 retail launch, in-market sales trends remain positive.
Importantly, the company has reduced its base operating expenses by 34% year-on-year, reflecting tighter cost control. Operating costs fell to $650,000 in the December quarter, down from $979,000 in December 2024. This improved financial discipline, combined with revenue growth, is expected to reduce net cash burn and move Firebrick closer to profitability.
Outlook and Strategic Focus
Firebrick’s recent activities underscore a strategic pivot towards international market expansion, product diversification, and financial sustainability. The company’s focus on regulatory approvals, particularly in the Philippines, and expanded promotional efforts in the US and Southeast Asia will be critical to watch in coming quarters.
With a solid foundation of user validation and improving financial metrics, Firebrick appears well positioned to capitalise on growing demand for povidone-iodine based respiratory protection products globally.
Bottom Line?
Firebrick Pharma’s strategic product launches and disciplined cost management set the stage for accelerated growth and potential profitability ahead.
Questions in the middle?
- How will the Philippines FDA approval process impact Firebrick’s Southeast Asia expansion timeline?
- What effect will expanded US retail distribution have on quarterly sales momentum?
- Can Firebrick sustain its reduced operating costs while scaling international operations?